After diagnosing dysautonomia, medical providers will often recommend a course of treatment that can include non-pharmacological lifestyle changes and prescription management.

Usually, non-pharmacological lifestyle changes are started first as these generally have fewer side effects and risks associated with them. Medications can be prescribed later if these interventions are not effective on their own.

Medications can also be prescribed to help improve symptoms while starting the lifestyle changes if symptoms are particularly severe and debilitating ¹ ².

Untitled design - 2021-12-07T124417.498
Untitled design - 2021-12-07T124810.606

Treatment for dysautonomia is typically individualized.

While one medication or supplement may help one person, there is no guarantee that treatment will work for you.

Prescription medications require patience and some trial and error while working with your provider in order to find the proper regimen.

At this time, treatment for dysautonomia is based on improving symptoms and quality of life; there is no cure. Many of the common medications used with dysautonomia patients are not approved by the Food and Drug Administration (FDA) to treat dysautonomia. These medications are being used “off-label,” meaning that they have been approved for use by the FDA to treat other conditions but have not been approved to treat dysautonomia.

The following provides information related to common medications that are used in the treatment of dysautonomia.

The purpose of this information is to empower our patients to ask questions and collaborate with their providers. However, this is not an all-inclusive list and does not contain all information related to medication use.

Please discuss all treatments, medication, and supplement use with your medical provider and pharmacist and take medications as prescribed.

Reviewed by Medical Content Experts, 2021

REFERENCES

Bryarly, M., Philips, L. T., Fu, Q., Vernino, S., & Levine, B.D. (2019). Postural orthostatic tachycardia syndrome: JACC focus seminar. Journal of the American College of Cardiology, 73(10). 1207-1222. {1,15, 25, 33, 44, 50, 70, 83, 84, 85, 87, 105, 111, 115 }

Cerner Multum. (2020, September 2). Octreotide (oral/injection). Drugs.com. Retrieved, July 27, 2021 {97, 101, 102}

Cerner Multum. (2020, November 9). Pyridostigmine. Drugs.com. Retrieved, July 28, 2021 {113)

Cerner Multum. (2021, Jan 14). Desmopressin. Drugs.com. Retrieved, July 27, 2021 {30}

Cerner Multum. (2021, Feb 8). Droxidopa. Drugs.com. Retrieved, July 27, 2021 {37}

Cerner Multum. (2021, April 13). Modafinil. Drugs.com. Retrieved, July 28, 2021 {90, 95, 96}

Drugs.com. (2020, July 4). Yohimbine (oral). Retrieved, July 28, 2021 {123, 126}

Drugs.com. (2021, July 13). Amphetamine. Retrieved, July 27, 2021 {8}

Fedorowski, A. (2019). Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management. Journal of Internal Medicine, 285(4), 352–366. {11, 13, 19, 21, 31, 34, 38, 42, 48, 59, 79, 103, 106}

Freeman, K., Goldstein, D.S., & Thompson, C.R. (2015). The dysautonomia project: Understanding autonomic nervous system dysfunction for physicians and patients. Bardolf & Company. {3, 7, 10, 14, 17, 20, 27, 32, 36, 41, 45, 47, 52, 58, 64, 65, 80, 86, 89, 98, 116, 117, 118, 121, 124, 125, 127}

Fookes, C. (2018). Selective serotonin reuptake inhibitors. Drugs.com. Retrieved, July 28, 2021 {114, 119, 120}

Goldstein, D.S. (n.d.). Principles of Autonomic Medicine 4.0.

Lehne, R. A. (2010 ). Pharmacology for Nursing Care (7th ed.). W.B Saunders Company.  {5}

Mar, P. L., Raj, V., Black, B. K., Biaggioni, I., Shibao, C. A., Paranjape, S. Y., Dupont, W. D., Robertson, D., & Raj, S. R. (2014). Acute hemodynamic effects of a selective serotonin reuptake inhibitor in postural tachycardia syndrome: a randomized, crossover trial. Journal of Psychopharmacology, 28(2), 155–61. {9, 18, 26, 28}

Maxwell, A. J. (2020). Dysautonomia In D. Jovin (Ed.), Disjointed: Navigating the diagnosis and management of hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders. (1st ed., pp. 135-215). Hidden Stripes Publications, Inc. {4, 6, 23, 29, 43, 46, 51, 55, 68, 78, 88, 92, 94, 99, 100, 112}

Mayo Clinic Staff. (2019). Serotonin syndrome. {122}

Mayo Clinic Staff. (2021). St. John’s wort. 

Medline Plus. (2017). Methyldopa. U.S. National Library of Medicine. {77}

Miller, A. J., & Raj, S. R. (2018). Pharmacotherapy for postural tachycardia syndrome. Autonomic Neuroscience: Basic and Clinical, 1–0. {72, 74, 76}

Raj, S.R., Block, B.K., Biaggioni, I., Paranjape, S.Y., Ramirez, M., Dupont, W.D., & Robertson, D. (2009). Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: Less is more. Circulation, 120, 725-734.

Raj, S.R., Guzman, J.C., Harvey, P., Richer, L., Schondorf, R., Seifer, C., Thibodeau-Jerry, N., & Sheldon, R.S. (2020). Canadian cardiovascular society position statement on postural orthostatic tachycardia syndrome (POTS) and related disorders of chronic orthostatic intolerance. Canadian Journal of Cardiology, 36(3), 357-372.  {2, 12, 16, 22, 24, 39, 49, 53, 60, 61, 63, 67, 69, 71, 73, 82, 104, 107, 108, 109}

Ruzieh, M., Dasa, O., Pacenta, A., Karabin, B., & Grubb, B. (2017). Droxidopa in the treatment of postural orthostatic tachycardia syndrome. American Journal of Therapeutics, 24(2), 161. {35}

Schofield, J. R. & Chemali, K.R. (2018). How we treat autoimmune small-fiber polyneuropathy with immunoglobulin therapy. European Neurology, 80, 304-310. {57}

Shehata, N. (2021, February 25). Patient education: Intravenous immune globulin (IVIG) (beyond the basics). UpToDate. Retrieved, July 27, 2021 {54, 56}

Sheldon, R. S., Grubb, B. P., Olshansky, B., Shen, W. K., Calkins, H., Brignole, M., Raj, S. R., Krahn, A. D., Morillo, C. A., Stewart, J. M., Sutton, R., Sandroni, P., Friday, K. J., Hachul, D. T., Cohen, M. I., Lau, D. H., Mayuga, K. A., Moak, J. P., Sandhu, R. K., & Kanjwal, K. (2015). 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart rhythm, 12(6), e41–e63. {40, 62, 66, 75, 81, 91, 93, 110}

Scroll to Top